When Is a Biopsy-Proven Diagnosis Necessary Before Stereotactic Ablative Radiotherapy for Lung Cancer?

Article ID	Journal	Published Year	Pages	File Type
5954587	Chest	2014	8 Pages	PDF

Abstract

This model suggests that if there are concerns about morbidity related to biopsy for an SPN, a PET scan-directed SABR strategy is warranted when the prior probability of lung cancer exceeds a point estimate of 85%.

Keywords

PSA SPN EQ-5D SABR QALY overall survival probabilistic sensitivity analysis Stereotactic ablative radiotherapy quality-adjusted life year NSCLC Non-small cell lung cancer Chest true positive false positive false negative true negative American College of Chest Physicians Solitary pulmonary nodule

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Preview

When Is a Biopsy-Proven Diagnosis Necessary Before Stereotactic Ablative Radiotherapy for Lung Cancer?

Authors

Alexander V. MD, Suresh PhD, Pretesh MD, Bart S. MD, PhD, Frank J. MD, PhD, George B. MD, PhD, Joseph K. MD, Christopher MD, David A. MD, PhD, Myriam G. MD, PhD,